AllianceBernstein’s Apogee Therapeutics APGE Stock Holding History

AllianceBernstein’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.2M	Sell	775,058 -215,239	-22%	-$19.4M	0.02%	536
2026 Q1	$74.7M	Sell	990,297 -103,360	-9%	-$7.51M	0.02%	472
2025 Q4	$82.5M	Sell	1,093,657 -325,475	-23%	-$20.5M	0.03%	462
2025 Q3	$56.4M	Buy	1,419,132 +30,983	+2%	+$1.18M	0.02%	588
2025 Q2	$60.3M	Buy	1,388,149 +107,199	+8%	+$4.08M	0.02%	555
2025 Q1	$47.9M	Sell	1,280,950 -74,235	-5%	-$2.87M	0.02%	596
2024 Q4	$61.4M	Buy	1,355,185 +160,822	+13%	+$8.2M	0.02%	537
2024 Q3	$70.2M	Buy	1,194,363 +62,093	+5%	+$2.98M	0.02%	515
2024 Q2	$44.6M	Buy	1,132,270 +387,152	+52%	+$18.8M	0.02%	629
2024 Q1	$49.5M	Buy	745,118 +734,478	+6,903%	+$32.1M	0.02%	604
2023 Q4	$297K	Buy	+10,640	New	+$213K	﹤0.01%	2848

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

AllianceBernstein's APGE Position: Q2 2026 in Review

AllianceBernstein reduced its Apogee Therapeutics (APGE) stake by 22% in Q2 2026, selling an estimated $19.4M and leaving 775,058 shares worth $65.2M. The position accounts for 0.02% of the portfolio, ranked #536.

AllianceBernstein first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. The position peaked at $82.5M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

AllianceBernstein held 775,058 shares of Apogee Therapeutics worth $65.2M as of Q2 2026.
AllianceBernstein sold 215,239 Apogee Therapeutics shares in Q2 2026, an estimated $19.4M.
Apogee Therapeutics made up 0.02% of AllianceBernstein's portfolio in Q2 2026, its #536 holding.
AllianceBernstein first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
AllianceBernstein's Apogee Therapeutics position peaked at $82.5M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.